The EANM is the largest non-profit medical organisation dedicated to nuclear medicine in Europe. Since its establishment in 1985, the EANM has consistently aimed to provide an interactive platform for the sharing and discussion of cutting-edge developments in the field, fostering the exchange of knowledge on disease diagnosis and treatment. Nuclear medicine is a multi-professional, independent, me
dical discipline based on the application of probes labelled with radionuclides (radiopharmaceuticals) to both diagnose and treat various diseases, such as cancer. Its scope encompasses molecular imaging, image-guided procedures, and targeted radionuclide therapy. Nuclear medicine procedures target specific physio-pathological processes or features underlying a disease directly at the molecular level. Employing sophisticated hybrid technology and a multimodal approach, nuclear medicine ensures a comprehensive diagnostic map, fostering precision medicine to diagnose, prognosticate, administer targeted therapy, guide treatment, and monitor its effects on patients. As a leading organisation in the field, the EANM brings together professionals from different backgrounds, including nuclear medicine physicians, medical physicists, radiochemists, pharmacists, technologists and other experts working in nuclear medicine or related fields. The EANM also works closely with 40 European nuclear medicine national societies, 20 non-European affiliated societies, EU institutions, international bodies and other medical societies to bring nuclear medicine to the forefront. Globally recognised for its Annual Congress, which attracts more than 7,000 attendees each year, the EANM is also the driving force behind the European School of Multimodality Imaging & Therapy (ESMIT). ESMIT offers a broad spectrum of educational programmes designed to enhance expertise in the field.
